Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Subscribe To Our Newsletter & Stay Updated